Patients on any systemic corticosteroid therapy within one week before the planned date for first dose on study would not be eligible; exception: patients on physiologic replacement doses of corticosteroids are permitted
Systemic corticosteroid use within  days before planned start of study therapy
Patients have had no previous treatment except corticosteroid use
Ongoing corticosteroid use.
? days for prior systemic corticosteroid therapy.
? days for immune-suppressive-based treatment for any reason. Note: Use of inhaled or topical corticosteroid use for radiographic procedures is permitted. Note: The use of physiologic corticosteroid replacement therapy may be approved after consultation with the sponsor.
Untreated or symptomatic brain metastases requiring corticosteroid therapy (no corticosteroid use for this purpose in the preceding  weeks)
Use of systemic corticosteroid therapy within  weeks of study enrollment, including patients receiving replacement corticosteroid therapy; note: only topical, inhaled and intranasal steroid therapy is permitted
Corticosteroid therapy for  days prior to enrollment
Any patient receiving chronic corticosteroid administration prior to study enrollment is ineligible
Systemic corticosteroid therapy at doses of greater than  mg daily for therapeutic and not adrenal replacement indications (maintenance steroid use for adrenal insufficiency is permitted)
Patients may not be taking any corticosteroid for any reason while on study and all corticosteroids must be stopped two weeks prior to initiation of study drug
FOR ALL PHASES (Ib AND II): Systemic continuous corticosteroid therapy at a daily dose higher than  mg prednisone or equivalent is not allowed; patients may be using topical or inhaled corticosteroids; previous corticosteroid therapy must be stopped or reduced to the allowed dose at least  days prior to the first study drug administration; if a patient is on chronic corticosteroid therapy, corticosteroids should be de-escalated to the maximum allowed dose after the patient has signed the consent document
Systemic corticosteroid therapy of any dose is not allowed within  days prior to the required leukapheresis, or the initiation of the conditioning chemotherapy regimen; corticosteroid creams, ointments, and eye drops are allowed
Systemic corticosteroid steroid therapy of any dose is not allowed within  days prior to the required leukapheresis, or the initiation of the conditioning chemotherapy regimen; corticosteroid creams, ointments, and eye drops are allowed
Systemic oral corticosteroid treatment within  days prior to initiating treatment on study except as detailed above
Corticosteroid use within  weeks of study treatment
TREATMENT: Patients receiving systemic corticosteroid within  hours of CTL infusion
Chronic corticosteroid dependence (except replacement therapy)
Patients currently receiving chronic corticosteroid treatment (longer than  weeks duration) for management of pre-existing adverse events, or patients with a history of chronic corticosteroid treatment longer than  weeks' duration for AEs within  months of Screening are excluded
Systemic oral corticosteroid treatment within  days prior to initiating treatment on study
Chronic use of high-dose oral corticosteroid therapy .
Chronic adrenal failure or is receiving concurrent long-term corticosteroid therapy.
Concurrent systemic corticosteroid therapy within  weeks prior to randomization, except prophylactic use of steroids prior to paclitaxel administration
Patient is on any systemic corticosteroid therapy within one week before the planned date for first dose of treatment or on any other form of immuno-suppressive medication
PRE-REGISTRATION: Chronic corticosteroid dependence that is unable to be weaned to discontinue.
Treatment with systemic corticosteroid or immune-modulators =<  days prior to randomization
ARM A: Any corticosteroid use =<  days prior to registration
ARM B: Any corticosteroid use =<  days prior to registration
Chronic systemic or regular inhaled corticosteroid use within  days prior to initiation of protocol therapy
Current corticosteroid (other than replacement doses in patients who are hypo-adrenal) or other immunosuppressive therapy
Completed treatment with systemic corticosteroid or immune-modulators <  days prior to registration;
Use of systemic corticosteroid.
No oral or intravenous corticosteroid use within  weeks prior to study entry
Patients with adrenal insufficiency or patients currently requiring chronic, systemic corticosteroid therapy at any dose for longer than  weeks. Local steroid therapies (eg, otic, ophthalmic, intraarticular, or inhaled medications) are acceptable
Systemic corticosteroid (inhalers are allowed) within  days before the first dose of study drug.
Stable dose of non-corticosteroid immunosuppressants for the  weeks prior to first dose of AMG .
Have received systemic corticosteroid (inhalers are allowed) within  days before the first administration of study drug
Systemic corticosteroid therapy (ongoing)
No increase in corticosteroid dose in the week prior to baseline brain imaging
Known treatment with systemic corticosteroid within one week prior to the first administration of study drug
Corticosteroid monotherapy for lymphoma within  week of the first dose of study drug
Chronic or high-dose corticosteroid therapy
Patients who are on (or will require) prolonged systemic corticosteroid treatment during the study, except for:
History of chronic corticosteroid use
Continuous corticosteroid therapy within  days prior to first dose of orteronel
Asymptomatic with no corticosteroid requirements for >=  weeks prior to randomization, AND
Systemic corticosteroid therapy < days prior to first dose of the study medication
Have received a systemic corticosteroid within one week prior to the first administration of study drug;
Need for current chronic corticosteroid therapy
Steroids: Dose should be stable or decreasing for at least one week prior to starting therapy; corticosteroid therapy is permissible only for the treatment of increased intracranial pressure in patients with malignancies in the CNS or for spinal cord compression; corticosteroid should be used at the lowest dose to control symptoms and discontinued if possible
Subjects treated with systemic Corticosteroid (CST) within  week before randomization and subjects treated with infliximab within  weeks before randomization
Chronic systemic corticosteroid use (> days) at the time of study enrollment.
Any expected corticosteroid use during study enrollment at higher doses than will be used in this study.
Concurrent systemic corticosteroid therapy;
Subjects who have concurrent illness requiring systemic corticosteroid use other than the planned dexamethasone during conditioning therapy
Chronic systemic corticosteroid use (>  days) at the time of study enrollment
Corticosteroid within the past  days prior to registration on this study for greater than one week duration
Patient must be willing to remain on corticosteroid therapy for  days postoperatively
Patient who has been started on systemic corticosteroid therapy within  h prior to study drug administration or is planned to receive a corticosteroid as part of the chemotherapy regimen
Has started on systemic corticosteroid therapy within  hours prior to study drug administration or is expected to receive a corticosteroid as part of the chemotherapy regimen
Has not received Dex or another corticosteroid in over  weeks prior to enrollment
Systemic corticosteroid therapy within  days before enrollment.
